Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Helicobacter pylori (H. pylori) infection is a common global infectious disease of the
gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the
development of stomach cancer. Progressive application of dual therapy for the eradication of
Helicobacter pylori. Tegoprazan, a Potassium-Competitive Acid Blockers. The efficacy of P-CAB
agents represented by vonoprazan in H. pylori eradication therapy has been widely verified.
Phase:
N/A
Details
Lead Sponsor:
Yanqing Li
Collaborators:
Linyi People's Hospital The Affiliated Hospital of Qingdao University The People's Hospital of Jimo Weifang Medical University Yuncheng Traditional Chinese Medicine Hospital Zhengzhou Central Hospital